68776-57-8

Usage

Uses

Used in Organic Synthesis:
Isoxazole-3-Carbonitrile is used as a key intermediate in organic synthesis for the creation of various complex organic compounds. Its unique structure allows for a wide range of chemical reactions, making it a valuable component in the development of new molecules with specific properties.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Isoxazole-3-Carbonitrile is utilized as a building block for the synthesis of pharmaceutical compounds. Its derivatives have demonstrated biological activities that are beneficial in the treatment of various conditions, such as inflammation, pain, bacterial infections, and fungal infections.
Used in Research and Development:
Isoxazole-3-Carbonitrile is also used in research and development settings to explore its potential applications and to understand its chemical properties. This helps in the discovery of new compounds and the advancement of scientific knowledge in the field of chemistry and medicine.

Upstream product

• 29065-91-6 isoxazole-3-carboxamide 
• 64-19-7 acetic acid 
• 74-86-2 acetylene 
• 141-78-6 ethyl acetate 
• 15719-64-9 methylammonium carbonate 
• 75-05-8 acetonitrile 
• 1201794-84-4 5-ethoxy-4,5-dihydroisoxazole-3-carbonitrile 

Downstream Products

• 88511-37-9 1-(isoxazol-3-yl)ethan-1-one 
• 38791-02-5 isoxazol-3-yl(phenyl)methanone 
• 173304-32-0 3-[2-(2,5-dimethylphenoxymethyl)benzoyl]isoxazole 

Relevant academic research and scientific papers

COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES AND CANCER

The invention provides the imidazole, oxazole and thiazole compounds and use thereof in methods for treating a disease or a disorder, such as infectious diseases and cancer, wherein inhibition of sphingosine-1-phosphate lyase is beneficial to treat the disease or the disorder.

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: Discovery of (E)-1-(4-((1 R,2 S,3 R)-1,2,3,4-tetrahydroxybutyl)-1 H -imidazol-2-yl)ethanone oxime (LX2931) and (1 R,2 S,3 R)-1-(2-(Isoxazol-3-yl)-1 H -imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)

Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4- tetrahydroxybutyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.

METHYLENE AMINES OF THIENO [2,3-D] PYRIMIDINE AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS

This invention relates to a novel thieno[2,3-d]pyrimidine, A, and its therapeutic and prophylactic uses, wherein R1 and R2 are definedin the specification. Disorders treated and/or prevented include Parkinson's Disease.

SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE

Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use.

METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS

Methods of preparing compounds of formula I are disclosed: